We serve Chemical Name:2,5-DICHLOROBENZENESULFONIC ACID CAS:88-42-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,5-DICHLOROBENZENESULFONIC ACID
CAS.NO:88-42-6
Synonyms:EINECS 201-829-2;2,5-dichlorobenzenesulfonic acid;MFCD00035751
Molecular Formula:C6H4Cl2O3S
Molecular Weight:227.06500
HS Code:2904909090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.668g/cm3
Index of Refraction:1.603
PSA:62.75000
Exact Mass:225.92600
LogP:3.32090
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3261
Packing Group:
Contact us for information like EINECS 201-829-2 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00035751 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,5-dichlorobenzenesulfonic acid Use and application,2,5-dichlorobenzenesulfonic acid technical grade,usp/ep/jp grade.
Related News: Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds. 3-diethoxyphosphorylpropanenitrile manufacturers Only four out of the eight studies showed a reduction in ‘off’ time, and the effect did not increase with an increased dose of Nouryant.” (+/-)-matairesinol suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. Hemokinin 1 (mouse, rat) trifluoroacetate salt vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. Hemokinin 1 (mouse, rat) trifluoroacetate salt vendor & factory.
